Omicron: 2 doses of Sinopharm vaccine offers weak protection against new strain, finds study

The Omicron variant of the coronavirus evades immunity offered by an inactivated Covid-19 vaccine developed by Sinopharm, a lab study has found.

Researchers from the University of Washington and Swiss antibody therapeutics company Humabs BioMed investigated how the Omicron variant might escape immunity from past infections or vaccination by comparing the performance of plasma from recovered Covid-19 patients and people vaccinated with six major Covid-19 vaccines.